Introduction

Biocompatibility has long been treated as synonymous with testing.
Cytotoxicity, sensitization, irritation—run the tests, compile the reports, and move forward.

But under modern regulatory frameworks like EU MDR, this mindset is not only outdated—it can be inefficient, expensive, and sometimes unnecessary.

Today, regulators expect a risk-based, scientifically justified approach to biological safety. Testing is just one tool in that process—not the default starting point.

So the real question is:
Can you justify biocompatibility without new testing?

The answer is yes—if you do it right.

Understanding the Shift: From Testing to Justification

The foundation of this shift lies in ISO 10993, which emphasizes a biological evaluation plan (BEP) based on:

• Nature and duration of contact
• Material composition
• Existing data
• Risk assessment

This means manufacturers are not automatically required to perform all biological tests. Instead, they must justify why certain tests are or are not needed.

In other words, regulators are asking: Do you understand your device well enough to prove it is safe?

When Can Biocompatibility Be Justified Without Testing?

There are several scenarios where new testing may not be required:

1. Use of Well-Characterized Materials

If your device uses materials with:

• Known chemical composition
• Established safety profiles
• History of safe medical use

You may not need additional testing.

For example, common medical-grade polymers like polyethylene or silicone often have extensive historical data supporting their safety.

However, simply stating “commonly used material” is not enough.
You must demonstrate:

• Exact grade and formulation
• Manufacturing process impact
• Potential impurities or additives

2. Material Equivalence to Existing Devices

One of the most powerful strategies is demonstrating equivalence to a legally marketed device.

If you can show:

• Same material composition
• Same contact type and duration
• Similar manufacturing processes

You can leverage existing biocompatibility data.

But be careful—equivalence under EU MDR is strict. Even small differences (e.g., additives, colorants, sterilization methods) can invalidate your claim.

3. Supplier Data and Certifications

Many raw material suppliers provide:

• Biocompatibility test reports
• Toxicological data
• Compliance declarations

These can be used as supporting evidence—if properly evaluated.

The key is not to blindly accept supplier claims but to:

• Verify relevance to your device configuration
• Assess applicability based on contact conditions
• Address gaps through risk assessment

4. Literature-Based Evidence

Scientific literature can provide strong support for biological safety, especially when aligned with ISO 10993 endpoints.

This includes:

• Published toxicological data
• Clinical studies
• Material safety reviews

However, literature must be:

• Relevant to your exact material and use case
• Critically appraised
• Integrated into a structured justification

A random collection of papers will not pass review.
A coherent scientific argument will.

5. Toxicological Risk Assessment (TRA)

A toxicological risk assessment is often the backbone of a no-testing strategy.

This involves:

• Identifying chemical constituents (extractables/leachables)
• Estimating patient exposure
• Comparing exposure levels to safety thresholds

If exposure is below toxicological concern levels, risks can be considered acceptable without biological testing.

This approach is especially effective for:

• Limited contact devices
• Low-risk materials
• Well-characterized formulations

6. History of Clinical Use

If your device—or a very similar one—has been used clinically without adverse effects, this real-world evidence can support biocompatibility.

Sources include:

• Post-market surveillance data
• Complaint records
• Published clinical experience

Under EU MDR, such data must be systematically collected and evaluated—not just assumed

Why Most Justifications Fail

Despite these strategies, many submissions still get rejected.

Not because avoiding testing is wrong – but because the justification is weak.

Here are the most common mistakes:

1. Lack of Material Transparency

Incomplete information about composition, additives, or processing.

2. Poor Link to Device Use

Evidence is not aligned with actual contact type, duration, or patient population.

3. Over-Reliance on Supplier Claims

Using supplier data without critical evaluation.

4. No Risk-Based Rationale

Failing to explain why testing is unnecessary.

5. Fragmented Documentation

Data exists—but is not structured into a clear, defensible argument.

What Notified Bodies Actually Expect

Notified Bodies are not against avoiding testing.
They are against unjustified assumptions.

A strong biocompatibility justification should include:

• A clear Biological Evaluation Plan (BEP)
• Comprehensive material characterization
• Identification of all relevant biological endpoints
• A risk-based rationale for excluding tests
• Supporting data (literature, supplier info, TRA, clinical data)
• A well-structured Biological Evaluation Report (BER)

The goal is simple: – Show that all potential biological risks have been identified, assessed, and controlled.

The Strategic Advantage of Avoiding Unnecessary Testing

When done correctly, a no-testing approach offers significant benefits:

• Reduced time to market
• Lower costs
• Avoidance of redundant animal testing
• Stronger scientific understanding of the device

More importantly, it demonstrates regulatory maturity—something increasingly valued under EU MDR.

Final Thoughts

Biocompatibility is no longer about ticking boxes.
It’s about building a scientifically sound, risk-based justification.

Testing is not the gold standard—
justification is.

If you understand your materials, your device, and your risks,
you can often demonstrate safety without running a single new test.

But this requires more than data.
It requires strategy, structure, and regulatory insight.

Because in today’s regulatory landscape,
it’s not about how much testing you do—
it’s about how well you justify what you don’t.